DOCSLIB.ORG

IL-9 Induces Differentiation of TH17 Cells and Enhances Function of Foxp3؉ Natural Regulatory T Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IL-9 Induces Differentiation of TH17 Cells and Enhances Function of Foxp3؉ Natural Regulatory T Cells IL-9 induces differentiation of TH17 cells and enhances function of FoxP3؉ natural regulatory T cells Wassim Elyamana, Elizabeth M. Bradshawa, Catherine Uyttenhoveb, Vale´ rie Dardalhona, Amit Awasthia, Jaime Imitolaa, Estelle Bettellia, Mohamed Oukkaa, Jacques van Snickb, Jean-Christophe Renauldb, Vijay K. Kuchrooa, and Samia J. Khourya,1 aCenter for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 and bLudwig Institute for Cancer Research and Experimental Medicine Unit, Universite´Catholique de Louvain, Brussels, Belgium Edited by Richard A. Flavell, Yale University School of Medicine, New Haven, CT, and approved March 31, 2009 (received for review December 11, 2008) The development of T helper (TH)17 and regulatory T (Treg) cells is ing large amounts of IL-10, but induce severe colitis and peripheral reciprocally regulated by cytokines. Transforming growth factor neuritis upon adoptive transfer into immune deficient hosts (14). ؉ ␤ (TGF)- alone induces FoxP3 Treg cells, but together with IL-6 or IL-21 Another recent report describes reprogramming of TH2 cells by induces TH17 cells. Here we demonstrate that IL-9 is a key molecule TGF-␤ to cells producing IL-9 and IL-10 (11), and these cells were that affects differentiation of TH17 cells and Treg function. IL-9 pre- also shown to have effector and not regulatory functions. These ␤ dominantly produced by TH17 cells, synergizes with TGF- 1 to differ- data suggest that IL-9/IL-10-producing T cells are not regulatory T ؉ entiate naïve CD4 T cells into TH17 cells, while IL-9 secretion by TH17 cells but effector T cells that induce tissue inflammation. However, cells is regulated by IL-23. Interestingly, IL-9 enhances the suppressive whether these effector functions are mediated by IL-9 and what role ؉ ؉ functions of FoxP3 CD4 Treg cells in vitro, and absence of IL-9 does IL-9 play in pathogenicity of this unique subset of T cells has signaling weakens the suppressive activity of nTregs in vivo, leading not been evaluated. to an increase in effector cells and worsening of experimental auto- In the present study, we show that TH17 cells produce large immune encephalomyelitis. The mechanism of IL-9 effects on TH17 IMMUNOLOGY quantities of IL-9 that act on both TH17 and Treg cells. In the and Tregs is through activation of STAT3 and STAT5 signaling. Our presence of TGF-␤, IL-9 differentiates naïve CD4ϩ T cells into findings highlight a role of IL-9 as a regulator of pathogenic versus TH17 cells. Paradoxically, IL-9 also acts on nTregs and enhances their protective mechanisms of immune responses. suppressive function in vitro and in vivo. Mice lacking IL-9 receptor (IL-9RϪ/Ϫ) exhibit a more severe course of experimental autoim- ͉ ͉ autoimmunity regulatory cells tolerance mune encephalomyelitis (EAE) and have a defect in the suppressive activity of Tregs. n the presence of antigen stimulation, naïve CD4ϩ T cells Iproliferate and differentiate into T helper type 1 (TH1) cells, TH2 Results cells, or interleukin-17 (IL-17)-producing T helper cells (TH17 cells) IL-9 Is Produced by TH17 Cells. TH17 cells produce several cytokines to exert specific effector functions. TH17 cells express the transcrip- including IL-17, IL-21, and IL-22 (2). We sought to determine the ␥ tion factor retinoic acid orphan receptor gamma (ROR- )t (1), additional cytokines that are secreted by TH17 cells. FACS-sorted participate in the control of extracellular pathogens, and have an naïve CD4ϩCD62LhiFoxP3Ϫ T cells isolated from FoxP3.GFP important role in human and experimental autoimmunity (2). TH17 ‘‘knock-in’’ (FoxP3.GFP.KI) reporter mice were differentiated into cells have been identified as major inducers of tissue inflammation TH1, TH2, and TH17 according to established protocols (Fig. S1A). and autoimmunity. Since exaggerated responses of TH1, TH2, and Inducible Tregs(iTregs) (7) were generated by activating TH17 cells can induce tissue inflammation, the maintenance of CD4ϩCD62LhiFoxP3Ϫ T cells in the presence of TGF-␤ (Fig. S1B), immune homeostasis and prevention of immunopathology is me- and nTregs were sorted from naïve FoxP3.GFP.KI mice based on in diated by subsets of T cells called regulatory T cells (Tregs). Treg cell vivo FoxP3 expression (Fig. S1C). Using multiplex bead-based differentiation and function are driven by the transcription factor Luminex technology, we identified IL-9 as a dominant cytokine forkhead box P3 (FoxP3) (3, 4), and they are closely related to the ␤ produced both by TH2 and TH17 cells (Fig. 1A). These data were generation of TH17 cells. Transforming growth factor (TGF)- 1 confirmed by quantitative Taqman PCR (Fig. 1A) and by flow induces the differentiation of T cells (5), whereas TGF-␤1in reg cytometry (Fig. 1B). Moreover, IL-9 was not detected in the combination with IL-6 (6, 7) or IL-21 (8) results in the differenti- supernatants of nT or iT (Fig. 1A), but IL-9R mRNA was ation of T 17 cells. regs reg H highly expressed by nT and not by iT (Fig. 1A). IL-9 is a T cell-derived factor preferentially expressed by T 2 regs regs H Naïve CD4ϩ T cells activated with plate-bound anti-CD3 and cells (9), although a previous study suggested that regulatory T cells anti-CD28 in the presence of recombinant mouse IL-9 had in- produce more IL-9 than TH2 cells (10); however this was not creased secretion of the TH2 (IL-4, IL-10, and IL-13), cytokines, confirmed in induced (iTregs) or natural (nTregs) (11). It is a ␥ pleiotropic cytokine that targets cells of the lymphoid, myeloid, and and at the same time down-regulated IFN (IFN)- and granulocyte- mast cell lineages, as well as lung epithelial cells. IL-9 activities are macrophage colony stimulation factor (GM-CSF) production (Fig. mediated by a specific IL-9 receptor chain that forms a het- erodimeric receptor with the common gamma chain (␥c) also Author contributions: W.E., C.U., J.I., J.V.S., J.-C.R., and S.J.K. designed research; W.E., involved in IL-2, 4, 7, 15, and 21 signaling. The IL-9 receptor and E.M.B., C.U., V.A.D., A.A., and J.V.S. performed research; C.U., E.B., M.O., J.V.S., J.-C.R., and ␥c associate with Janus kinase (JAK)1 and JAK3, respectively, and V.K.K. contributed new reagents/analytic tools; W.E., E.M.B., C.U., V.A.D., and J.V.S. ana- trigger the activation of STAT1, 3, and 5 (12, 13). Dysregulated IL-9 lyzed data; and W.E. wrote the paper. response in vitro can lead to autonomous cell growth and malignant The authors declare no conflict of interest. transformation of lymphoid cells associated with constitutive acti- This article is a PNAS Direct Submission. vation of the JAK/STAT pathway (12). We have recently described 1To whom correspondence should be addressed. E-mail: [email protected]. a subset of T cells that predominantly produces IL-9 together with This article contains supporting information online at www.pnas.org/cgi/content/full/ IL-10 and do not exhibit any regulatory properties despite produc- 0812530106/DCSupplemental. www.pnas.org͞cgi͞doi͞10.1073͞pnas.0812530106 PNAS Early Edition ͉ 1of6 Downloaded by guest on September 28, 2021 A B Th1 Th2 Th17 0.12 0.18 1.13 0.64 3.56 1.04 5 5 5 iTregs 10 10 10 nTregs 4 10 104 104 Th17 9 3 - 10 103 103 Th2 L I 2 Th1 10 102 102 Th0 0 0 0 67.6 32.1 84.2 13.9 82.8 12.6 0 50 100 150 200 250 300 350 400 450 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 0 1 2 3 4 5 6 7 8 9 0 102 103 104 105 0102 103 104 105 0102 103 104 105 IL-9 (pg/ml) IL-9 relative expression IL-9R relative expression IFN-γ IL-10 IL-17 TGF-β1 TGF-β1 C IL-4 IFN-γ 200 TGF-β 500 *** IL-21 400 IL-9 IL-6 300 100 IL-6 + TGF-β 200 IL-21 + TGF-β IL9 + TGF-β 100 No cytokine 0 0 0 100 200 300 0 100 200 300 400 500 no cytokine IL-9 no cytokin IL-9 pg/ml pg/ml ϩ hi Ϫ Fig. 1. TH17 cells produce IL-9. CD4 CD62L FoxP3/GFP T cells from FoxP3-GFP.KI mice were stimulated with anti-CD3 and anti-CD28 for 3–5 days in the presence of the corresponding cytokines. (A) IL-9 relative expression as determined by bead-based Luminex assay (left) and by quantitative RT-PCR (middle) and IL-9 ϩ hi receptor relative expression (right) in TH0, TH1, TH2, TH17, nTregs, and iTregs.(B) Intracellular staining of cytokines in naïve CD4 CD62L T cells from B6 mice sorted ϩ by flow cytometry and cultured for 4 days in TH1, TH2, or TH17 conditions. (C) Effects of IL-9 on the production of IL-4, IFN-␥, and TGF-␤1 by naïve CD4 T cells as measured by bead-based Luminex assay. For TGF-␤1 assay, supernatants were ‘‘acid-treated’’ followed by bead-based Luminex assay. Effect of IL-9 on TGF-␤1 expression in T cells was also measured by quantitative Taqman PCR. 1C and Fig. S2). Interestingly, cells exposed to IL-9 produce IL-9 might normally contribute to TH17 differentiation even when significant amounts of TGF-␤1 and this was confirmed by Taqman TH17 cells were differentiated by other cytokine cocktails (TGF-␤ PCR (Fig.
Load more

Recommended publications
  • Human Vδ2 T Cells Are a Major Source of Interleukin-9
    Human Vδ2 T cells are a major source of interleukin-9 Christian Petersa, Robert Häslerb, Daniela Wescha, and Dieter Kabelitza,1 aInstitute of Immunology, University Hospital Schleswig-Holstein Campus Kiel, D-24105 Kiel, Germany; and bInstitute of Clinical Molecular Biology, University Hospital Schleswig-Holstein Campus Kiel, D-24105 Kiel, Germany Edited by Willi K. Born, National Jewish Health, Denver, CO, and accepted by Editorial Board Member Philippa Marrack September 12, 2016 (received for review May 13, 2016) Vδ2Vγ9 T cells are the dominant γδ T-cell subset in human periph- Vδ2 T cells produce different cytokines, can be converted into + eral blood. Vδ2 T cells recognize pyrophosphate molecules derived forkhead box protein P3 (FoxP3) regulatory cells (20, 21), and from microbes or tumor cells; hence, they play a role in antimicro- may acquire professional antigen-presenting capacity (22). Depend- bial and antitumor immunity. TGF-β, together with IL-15, induces ing on priming conditions, Vδ2 T cells can secrete IFN-γ,IL-4,IL- a regulatory phenotype in Vδ2 T cells, characterized by forkhead 17, and IL-22, and thus recapitulate cytokine patterns of well-defined box protein P3 (FoxP3) expression and suppressive activity on CD4 functional Th subsets (23, 24). T-cell activation. We performed a genome-wide transcriptome Here, we identified peripheral blood Vδ2Tcellsasamajorsource analysis and found that the same conditions (TGF-β plus IL-15) of IL-9. In the presence of TGF-β and IL-15 but the absence of IL-4, strongly enhanced the expression of additional genes in Vδ2T high levels of IL-9 were secreted already 4 d after initial in vitro ac- cells, including IKAROS family zinc finger 4 (IKZF4; Eos), integrin tivation.
    [Show full text]
  • Interleukin-9 Regulates Macrophage Activation in the Progressive Multiple Sclerosis Brain
    Donninelli et al. Journal of Neuroinflammation (2020) 17:149 https://doi.org/10.1186/s12974-020-01770-z RESEARCH Open Access Interleukin-9 regulates macrophage activation in the progressive multiple sclerosis brain Gloria Donninelli1†, Inbar Saraf-Sinik1,2†, Valentina Mazziotti3, Alessia Capone1,4, Maria Grazia Grasso5, Luca Battistini1, Richard Reynolds6, Roberta Magliozzi3,6*† and Elisabetta Volpe1*† Abstract Background: Multiple sclerosis (MS) is an immune-mediated, chronic inflammatory, and demyelinating disease of the central nervous system (CNS). Several cytokines are thought to be involved in the regulation of MS pathogenesis. We recently identified interleukin (IL)-9 as a cytokine reducing inflammation and protecting from neurodegeneration in relapsing–remitting MS patients. However, the expression of IL-9 in CNS, and the mechanisms underlying the effect of IL-9 on CNS infiltrating immune cells have never been investigated. Methods: To address this question, we first analyzed the expression levels of IL-9 in post-mortem cerebrospinal fluid of MS patients and the in situ expression of IL-9 in post-mortem MS brain samples by immunohistochemistry. A complementary investigation focused on identifying which immune cells express IL-9 receptor (IL-9R) by flow cytometry, western blot, and immunohistochemistry. Finally, we explored the effect of IL-9 on IL-9-responsive cells, analyzing the induced signaling pathways and functional properties. Results: We found that macrophages, microglia, and CD4 T lymphocytes were the cells expressing the highest levels of IL-9 in the MS brain. Of the immune cells circulating in the blood, monocytes/macrophages were the most responsive to IL-9. We validated the expression of IL-9R by macrophages/microglia in post-mortem brain sections of MS patients.
    [Show full text]
  • Cytokine Modulators As Novel Therapies for Airway Disease
    Copyright #ERS Journals Ltd 2001 Eur Respir J 2001; 18: Suppl. 34, 67s–77s European Respiratory Journal DOI: 10.1183/09031936.01.00229901 ISSN 0904-1850 Printed in UK – all rights reserved ISBN 1-904097-20-0 Cytokine modulators as novel therapies for airway disease P.J. Barnes Cytokine modulators as novel therapies for airway disease. P.J. Barnes. #ERS Correspondence: P.J. Barnes Journals Ltd 2001. Dept of Thoracic Medicine ABSTRACT: Cytokines play a critical role in orchestrating and perpetuating National Heart & Lung Institute inflammation in asthma and chronic obstructive pulmonary disease (COPD), and Imperial College Dovehouse Street several specific cytokine and chemokine inhibitors are now in development for the future London SW3 6LY therapy of these diseases. UK Anti-interleukin (IL)-5 is very effective at reducing peripheral blood and airway Fax: 0207 3515675 eosinophil numbers, but does not appear to be effective against symptomatic asthma. Inhibition of IL-4 with soluble IL-4 receptors has shown promising early results in Keywords: Chemokine receptor asthma. Inhibitory cytokines, such as IL-10, interferons and IL-12 are less promising, cytokine as systemic delivery causes side-effects. Inhibition of tumour necrosis factor-a may be interleukin-4 useful in severe asthma and for treating severe COPD with systemic features. interleukin-5 interleukin-9 Many chemokines are involved in the inflammatory response of asthma and COPD interleukin-10 and several low-molecular-weight inhibitors of chemokine receptors are in development. CCR3 antagonists (which block eosinophil chemotaxis) and CXCR2 antagonists (which Received: March 26 2001 block neutrophil and monocyte chemotaxis) are in clinical development for the Accepted April 25 2001 treatment of asthma and COPD respectively.
    [Show full text]
  • Evolutionary Divergence and Functions of the Human Interleukin (IL) Gene Family Chad Brocker,1 David Thompson,2 Akiko Matsumoto,1 Daniel W
    UPDATE ON GENE COMPLETIONS AND ANNOTATIONS Evolutionary divergence and functions of the human interleukin (IL) gene family Chad Brocker,1 David Thompson,2 Akiko Matsumoto,1 Daniel W. Nebert3* and Vasilis Vasiliou1 1Molecular Toxicology and Environmental Health Sciences Program, Department of Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO 80045, USA 2Department of Clinical Pharmacy, University of Colorado Denver, Aurora, CO 80045, USA 3Department of Environmental Health and Center for Environmental Genetics (CEG), University of Cincinnati Medical Center, Cincinnati, OH 45267–0056, USA *Correspondence to: Tel: þ1 513 821 4664; Fax: þ1 513 558 0925; E-mail: [email protected]; [email protected] Date received (in revised form): 22nd September 2010 Abstract Cytokines play a very important role in nearly all aspects of inflammation and immunity. The term ‘interleukin’ (IL) has been used to describe a group of cytokines with complex immunomodulatory functions — including cell proliferation, maturation, migration and adhesion. These cytokines also play an important role in immune cell differentiation and activation. Determining the exact function of a particular cytokine is complicated by the influence of the producing cell type, the responding cell type and the phase of the immune response. ILs can also have pro- and anti-inflammatory effects, further complicating their characterisation. These molecules are under constant pressure to evolve due to continual competition between the host’s immune system and infecting organisms; as such, ILs have undergone significant evolution. This has resulted in little amino acid conservation between orthologous proteins, which further complicates the gene family organisation. Within the literature there are a number of overlapping nomenclature and classification systems derived from biological function, receptor-binding properties and originating cell type.
    [Show full text]
  • IL-9-Producing Invariant NKT Cells Protect Against DSS-Induced Colitis in an IL-4-Dependent Manner
    nature publishing group ARTICLES See COMMENTARY page XX IL-9-producing invariant NKT cells protect against DSS-induced colitis in an IL-4-dependent manner H S K i m 1 a n d D H C h u n g 1 Although the T-helper type 9 (Th9) subset has recently been revisited, interleukin (IL)-9-producing invariant natural killer T (iNKT) cells remain poorly characterized. Moreover, whether IL-9-producing iNKT cells regulate colitis is unknown. Here, we investigated functions of IL-9-producing iNKT cells in dextran sulfate sodium (DSS)-induced colitis. Wild- type (WT) mice attenuated colitis compared to J 18 − / − mice, which were restored by the adoptive transfer of WT, but not IL-4-deficient iNKT cells. IL-4-deficient iNKT cells failed to produce IL-9, which was reversed by recombinant IL-4. Furthermore, iNKT cells, pre-incubated with anti-CD3 + CD28 monoclonal antibodies and IL-4 + tumor growth factor (TGF)- (IL-9 + iNKT), suppressed colitis in J 18 − / − mice, whereas pre-incubated IL-4-deficient iNKT cells did not. IL-9 blockade reversed IL-9 + iNKT cell-mediated colitis by increasing colonic IL-17A and interferon (IFN)- transcripts, but decreasing IL-9, IL-10, TGF- , PU.1, IFN regulatory factor 4, and signal transducer and activator of transcription 5 in J 18 − / − mice. In conclusion, IL-9-producing iNKT cells protect against DSS-induced colitis through IFN- and IL-17A suppression, but IL-10 and TGF- enhancement, depending on the IL-4 production by iNKT cells. INTRODUCTION recognize glycolipids presented by CD1d, a major histocom- Diverse CD4 + T-cell subsets regulate immune responses patibility complex (MHC) class I-like protein expressed by to transplantation, infection, tumor surveillance, and auto- antigen-presenting cells.
    [Show full text]
  • Techniques for Immune Function Analysis Application Handbook 1St Edition
    Techniques for Immune Function Analysis Application Handbook 1st Edition BD Biosciences For additional information please access the Immune Function Homepage at www.bdbiosciences.com/immune_function For Research Use Only. Not for use in diagnostic or therapeutic procedures. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton Dickinson and Company is strictly prohibited. All applications are either tested in-house or reported in the literature. See Technical Data Sheets for details. BD, BD Logo and all other trademarks are the property of Becton, Dickinson and Company. ©2003 BD Table of Contents Preface . 4 Chapter 1: Immunofluorescent Staining of Cell Surface Molecules for Flow Cytometric Analysis . 9 Chapter 2: BD™ Cytometric Bead Array (CBA) Multiplexing Assays . 35 Chapter 3: BD™ DimerX MHC:Ig Proteins for the Analysis of Antigen-specific T Cells. 51 Chapter 4: Immunofluorescent Staining of Intracellular Molecules for Flow Cytometric Analysis . 61 Chapter 5: BD FastImmune™ Cytokine Flow Cytometry. 85 Chapter 6: BD™ ELISPOT Assays for Cells That Secrete Biological Response Modifiers . 109 Chapter 7: ELISA for Specifically Measuring the Levels of Cytokines, Chemokines, Inflammatory Mediators and their Receptors . 125 Chapter 8: BD OptEIA™ ELISA Sets and Kits for Quantitation of Analytes in Serum, Plasma, and Cell Culture Supernatants. 143 Chapter 9: BrdU Staining and Multiparameter Flow Cytometric Analysis of the Cell Cycle . 155 Chapter 10: Cell-based Assays for Biological Response Modifiers . 177 Chapter 11: BD RiboQuant™ Multi-Probe RNase Protection Assay System .
    [Show full text]
  • Human Cytokine Response Profiles
    Comprehensive Understanding of the Human Cytokine Response Profiles A. Background The current project aims to collect datasets profiling gene expression patterns of human cytokine treatment response from the NCBI GEO and EBI ArrayExpress databases. The Framework for Data Curation already hosted a list of candidate datasets. You will read the study design and sample annotations to select the relevant datasets and label the sample conditions to enable automatic analysis. If you want to build a new data collection project for your topic of interest instead of working on our existing cytokine project, please read section D. We will explain the cytokine project’s configurations to give you an example on creating your curation task. A.1. Cytokine Cytokines are a broad category of small proteins mediating cell signaling. Many cell types can release cytokines and receive cytokines from other producers through receptors on the cell surface. Despite some overlap in the literature terminology, we exclude chemokines, hormones, or growth factors, which are also essential cell signaling molecules. Meanwhile, we count two cytokines in the same family as the same if they share the same receptors. In this project, we will focus on the following families and use the member symbols as standard names (Table 1). Family Members (use these symbols as standard cytokine names) Colony-stimulating factor GCSF, GMCSF, MCSF Interferon IFNA, IFNB, IFNG Interleukin IL1, IL1RA, IL2, IL3, IL4, IL5, IL6, IL7, IL9, IL10, IL11, IL12, IL13, IL15, IL16, IL17, IL18, IL19, IL20, IL21, IL22, IL23, IL24, IL25, IL26, IL27, IL28, IL29, IL30, IL31, IL32, IL33, IL34, IL35, IL36, IL36RA, IL37, TSLP, LIF, OSM Tumor necrosis factor TNFA, LTA, LTB, CD40L, FASL, CD27L, CD30L, 41BBL, TRAIL, OPGL, APRIL, LIGHT, TWEAK, BAFF Unassigned TGFB, MIF Table 1.
    [Show full text]
  • The Deleterious Impact of Interleukin 9 to Hepatorenal Physiology
    Inflammation, Vol. 42, No. 4, August 2019 (# 2019) DOI: 10.1007/s10753-019-00997-0 ORIGINAL ARTICLE The Deleterious Impact of Interleukin 9 to Hepatorenal Physiology Nadjania Saraiva de Lira Silva,1,2 Bruna Cristina Borges,2 Aline Alves da Silva,2 Patrícia de Castilhos,2 Thaíse Lara Teixeira,2 Samuel Cota Teixeira,2 Marlus Alves dos Santos,2 João Paulo Silva Servato,3 Allisson Benatti Justino,4 Douglas Carvalho Caixeta,4 Tatiana Carla Tomiosso,2 Foued Salmen Espindola,4 and Claudio Vieira da Silva 2,5 Abstract— IL-9 is a pleiotropic cytokine, recently recognized as belonging to Th9 cells that are involved in various pathologies. We aimed to evaluate the role of IL-9 in the course of hepatic and renal fibrosis. Female C57BL/6 mice were treatedsubcutaneouslywithIL-910ng/mouseand 20 ng/mouse for 40 days, alternating every 5 days each application, the negative control of which was treated with PBS and positive control with CCL4. IL-9 demonstrated fibrogenic activity, leading to increased collagen I and III deposition in both liver and kidney, as well as triggering lobular hepatitis. In addition, IL-9 induced an inflammatory response with recruitment of lymphocytes, neutrophils, and macrophages to both organs. The inflammation was present in the region of the portal and parenchymal zone in the liver and in the cortical and medullary zone in the kidney. IL-9 deregulated liver and kidney antioxidant activities. Our results showed that IL-9 was able to promote hepatorenal dysfunction. Moreover, IL-9 poses as a promising target for therapeutic interventions. KEY WORDS: fibrosis; liver; kidney; inflammation; interleukin 9; oxidative stress.
    [Show full text]
  • UKPMC Funders Group Author Manuscript J Allergy Clin Immunol
    UKPMC Funders Group Author Manuscript J Allergy Clin Immunol. Author manuscript; available in PMC 2012 June 28. Published in final edited form as: J Allergy Clin Immunol. 2012 April ; 129(4): 1000–10.e3. doi:10.1016/j.jaci.2011.12.965. UKPMC Funders Group Author Manuscript UKPMC Funders Group Author Manuscript Activin A and TGF-β promote TH9 cell–mediated pulmonary allergic pathology Carla P. Jones, PhD*, Lisa G. Gregory, PhD*, Benjamin Causton, BSc, Gaynor A. Campbell, PhD, and Clare M. Lloyd, PhD Leukocyte Biology Section, Faculty of Medicine, National Heart and Lung Institute, Imperial College, London, United Kingdom Abstract Background—IL-9-secreting (TH9) T cells are thought to represent a distinct T-cell subset. However, evidence for their functionality in disease is uncertain. Objective—To define a functional phenotype for TH9-driven pathology in vivo. Methods—We used fluorescence-activated cell sorting to identify circulating TH9 cells in atopic and nonatopic subjects. In mice we utilized a model of allergic airways disease induced by house dust mite to determine TH9 cell function in vivo and the role of activin A in TH9 generation. Results—Allergic patients have elevated TH9 cell numbers in comparison to nonatopic donors, which correlates with elevated IgE levels. In a murine model, allergen challenge with house dust mite leads to rapid TH9 differentiation and proliferation, with much faster kinetics than for TH2 cell differentiation, resulting in the specific recruitment and activation of mast cells. The TGF-β superfamily member activin A replicates the function of TGF-β1 in driving the in vitro generation of TH9 cells.
    [Show full text]
  • An Update on Interleukin-9: from Its Cellular Source and Signal Transduction to Its Role in Immunopathogenesis
    International Journal of Molecular Sciences Review An Update on Interleukin-9: From Its Cellular Source and Signal Transduction to Its Role in Immunopathogenesis Sushmita Chakraborty 1,* , Katharina F. Kubatzky 2 and Dipendra Kumar Mitra 1,* 1 Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi 1100029, India 2 Zentrum für Infektiologie, Medizinische Mikrobiologie und Hygiene, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 324, 69120 Heidelberg, Germany; [email protected] * Correspondence: [email protected] (S.C.); [email protected] (D.K.M.); Tel.: +91-11-2659-4638 (D.K.M.) Received: 31 March 2019; Accepted: 24 April 2019; Published: 29 April 2019 Abstract: Interleukin-9 (IL-9) is a pleiotropic cytokine and was primarily studied in the context of T helper 2 (TH2)-associated immuno-pathological conditions such as asthma and parasitic infections. There was a paradigm shift in the biology of IL-9 after the recent discovery of TH9 cells, a new subtype of TH cells which secrete IL-9 in copious amounts. This has resulted in renewed interest in this cytokine, which was neglected since discovery because it was considered it to be just another TH2 cytokine. Recent studies have shown that it has multiple cellular sources and is critically involved in the immune-pathogenesis of inflammatory diseases and in guarding immune tolerance. In this review, we will discuss its discovery, gene organization, cellular sources, and signaling pathways. Especially, we will give an update on the recent development regarding its relevance in the immune pathogenesis of human diseases. Keywords: interleukin-9; inflammatory diseases; signal transduction 1.
    [Show full text]
  • Supplementary Data
    Gene Description Ref. Fold Change Name Sequence SK-OV-3 OVCAR-3 ABCF1 ATP-binding cassette, sub-family F (GCN20), NM_001090 - - member 1 BCL6 B-cell CLL/lymphoma 6 (zinc finger protein 51) NM_001706 - - C3 Complement component 3 NM_000064 - -1.54 C4A Complement component 4A (Rodgers blood NM_007293 - - group) C5 Complement component 5 NM_001735 13.74 - CCL1 Chemokine (C-C motif) ligand 1 NM_002981 - - CCL11 Chemokine (C-C motif) ligand 11 NM_002986 - - CCL13 Chemokine (C-C motif) ligand 13 NM_005408 - - CCL15 Chemokine (C-C motif) ligand 15 NM_032965 - - CCL16 Chemokine (C-C motif) ligand 16 NM_004590 - - CCL17 Chemokine (C-C motif) ligand 17 NM_002987 - - CCL18 Chemokine (C-C motif) ligand 18 (pulmonary and NM_002988 - - activation-regulated) CCL19 Chemokine (C-C motif) ligand 19 NM_006274 - 2.42 CCL2 Chemokine (C-C motif) ligand 2 NM_002982 - -2.23 CCL20 Chemokine (C-C motif) ligand 20 NM_004591 - - CCL21 Chemokine (C-C motif) ligand 21 NM_002989 - - CCL23 Chemokine (C-C motif) ligand 23 NM_005064 - - CCL24 Chemokine (C-C motif) ligand 24 NM_002991 - - CCL25 Chemokine (C-C motif) ligand 25 NM_005624 -1.49 2.59 CCL26 Chemokine (C-C motif) ligand 26 NM_006072 - - CCL3 Chemokine (C-C motif) ligand 3 NM_002983 - - CCL4 Chemokine (C-C motif) ligand 4 NM_002984 - - CCL5 Chemokine (C-C motif) ligand 5 NM_002985 - -1.54 CCL7 Chemokine (C-C motif) ligand 7 NM_006273 - - CCL8 Chemokine (C-C motif) ligand 8 NM_005623 - - CCR1 Chemokine (C-C motif) receptor 1 NM_001295 - 1.60 CCR2 Chemokine (C-C motif) receptor 2 NM_000648 - - CCR3 Chemokine (C-C
    [Show full text]
  • Features and Roles of T Helper 9 Cells and Interleukin 9 in Immunological Diseases
    Allergol Immunopathol (Madr). 2019;47(1):90---104 Allergologia et immunopathologia Sociedad Espa ˜nola de Inmunolog´ıa Cl´ınica, Alergolog´ıa y Asma Pedi ´atrica www.elsevier.es/ai REVIEW Features and roles of T helper 9 cells and interleukin 9 in immunological diseases a b b c b,∗ R. Yazdani , S. Shapoori , M. Rezaeepoor , R. Sanaei , M. Ganjalikhani-Hakemi , d,e f a a,g,h,∗ G. Azizi , W. Rae , A. Aghamohammadi , N. Rezaei a Research Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical Science, Tehran, Iran b Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran c Department of Immunology, School of Medicine, Iran University of Medical Science, Tehran, Iran d Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran e Department of Laboratory Medicine, Imam Hassan Mojtaba Hospital, Alborz University of Medical Sciences, Karaj, Iran f Department of Immunology, MP8, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, Hampshire SO16 6YD, UK g Department of Immunology, School of Medicine, Tehran University of Medical Science, Tehran, Iran h Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran Received 19 November 2017; accepted 9 February 2018 Available online 25 April 2018 KEYWORDS Abstract T helper 9 (TH9) cells are considered as newly classified helper T cells that have an TH9 cells; important role in the regulation of immune responses. Since these cells preferentially produce IL-9; IL-9, these cells are termed TH9 cells. Recently, the role of TH9 and its signature cytokine (IL-9) Autoimmunity; has been investigated in a wide range of diseases, including autoimmunity, allergy, infections, Allergic; cancer and immunodeficiency.
    [Show full text]